All In Biotech

Drug Trial Radar · NCT02299505

Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)

A Multi-center, Randomized Open Label Study to Assess the Systemic Exposure, Effiacy, and Safety of 450 mg Ceritinib Taken With a Low-fat Meal and 600 mg Ceritinib Taken With a Low-fat Meal as Compared With That of 750 mg Ceritinib Taken in the Fasted State in Adult Patients With ALK Rearranged (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)

Last checked: Nov 20, 2026Latest source record: Feb 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 306 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

306

Actual

Start

Apr 9, 2015

Primary completion

Jun 16, 2016

Study completion Mar 6, 2020

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 24, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase I study to assess the systemic exposure, effiacy, and safety of 450 mg ceritinib taken with a low-fat meal and 600 mg ceritinib taken with a low-fat meal as compared with that of 750 mg ceritinib taken in the fasted state in adult patients with ALK rearranged (ALK-positive) metastatic non-small cell lung cancer (NSCLC)

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • ceritinibDrug

    The investigational drug ceritinib was supplied to the Investigators as 150 mg capsules, for oral administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plasma concentration of ceritinibTime frame: Study Day 22

Locations

73 sites in 24 countries. Site status is shown where the registry gives one.

  • Highlands Oncology Group

    Fayetteville, Arkansas

  • Loma Linda University

    Loma Linda, California

  • Goshen Center for Cancer Care IU Health - SC

    Indianapolis, Indiana

  • Maryland Oncology Hematology, P.A. SC-2

    Rockville, Maryland

  • Essex Oncology of North Jersey PA SC

    Belleville, New Jersey

  • Greenville Health System SC

    Greenville, South Carolina

  • Utah Cancer Specialists Dept.of Utah Cancer Spec. (3)

    Salt Lake City, Utah

  • Novartis Investigative Site

    Auckland, Australia

  • Novartis Investigative Site

    Grafton, Auckland, Australia

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Edegem, Belgium

  • Novartis Investigative Site

    Natal, Rio Grande do Norte, Brazil

  • Novartis Investigative Site

    Passo Fundo, Rio Grande do Sul, Brazil

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site

    Itajaí, Santa Catarina, Brazil

  • Novartis Investigative Site

    Barretos, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Edmonton, Alberta, Canada

  • Novartis Investigative Site

    Hamilton, Ontario, Canada

  • Novartis Investigative Site

    Ottawa, Ontario, Canada

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Montería, Colombia

  • Novartis Investigative Site

    Brno, Czechia

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Cologne, Germany

  • Novartis Investigative Site

    Würzburg, Germany

  • Novartis Investigative Site

    Regensburg, Bavaria, Germany

  • Novartis Investigative Site

    Athens, Greece

  • Novartis Investigative Site

    Athens, GR, Greece

  • Novartis Investigative Site

    Delhi, India

  • Novartis Investigative Site

    Hyderabad, Andhra Pradesh, India

  • Novartis Investigative Site

    Bangalore, Karnataka, India

  • Novartis Investigative Site

    Nashik, Maharashtra, India

  • Novartis Investigative Site

    Kolkata, West Bengal, India

  • Novartis Investigative Site

    Novara, Italy

  • Novartis Investigative Site

    Bergamo, BG, Italy

  • Novartis Investigative Site

    Bologna, BO, Italy

  • Novartis Investigative Site

    Brescia, BS, Italy

Showing 40 of 73 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.